News Releases

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy

September 24, 2021
Combined company expected to begin trading on the Nasdaq Global Select Market under “JSPR” and “JSPRW” on or about September 27, 2021   REDWOOD CITY, Calif.--( BUSINESS WIRE )--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the

Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

May 19, 2021
New efficacy, safety and pharmacokinetic data in first six subjects to be presented in poster session at 2021 ASCO Annual Meeting At 90 days after transplant, measurable residual disease (MRD) as measured by cytogenetics, flow cytometry and next-generation sequencing was negative (undetected) in
Displaying 1 - 10 of 14

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.